Thursday, 30 Oct 2025
  • Contact
  • Privacy Policy
  • Terms & Conditions
  • DMCA
logo logo
  • World
  • Politics
  • Crime
  • Economy
  • Tech & Science
  • Sports
  • Entertainment
  • More
    • Education
    • Celebrities
    • Culture and Arts
    • Environment
    • Health and Wellness
    • Lifestyle
  • 🔥
  • Trump
  • VIDEO
  • House
  • White
  • ScienceAlert
  • Trumps
  • Watch
  • man
  • Health
  • Season
Font ResizerAa
American FocusAmerican Focus
Search
  • World
  • Politics
  • Crime
  • Economy
  • Tech & Science
  • Sports
  • Entertainment
  • More
    • Education
    • Celebrities
    • Culture and Arts
    • Environment
    • Health and Wellness
    • Lifestyle
Follow US
© 2024 americanfocus.online – All Rights Reserved.
American Focus > Blog > Health and Wellness > Novo’s New Weight Loss Drug Is More Effective Than Wegovy In Early Trial
Health and Wellness

Novo’s New Weight Loss Drug Is More Effective Than Wegovy In Early Trial

Last updated: September 11, 2024 7:50 am
Share
Novo’s New Weight Loss Drug Is More Effective Than Wegovy In Early Trial
SHARE

Novo Nordisk, the maker of Ozempic, has announced exciting new data regarding their upcoming weight loss pill. This pill, known as amycretin, has shown promising results in a Phase 1 clinical trial, with participants experiencing up to a 13% reduction in body weight over a 12-week period. The data was presented at the European Association for the Study of Diabetes conference in Madrid.

In the trial, patients taking either one or two 50mg amycretin pills per day saw significant weight loss compared to those on a placebo. Those taking two pills a day experienced a 13% weight loss, while those on one pill saw over a 10% reduction. This data suggests that amycretin may lead to greater and more rapid weight loss compared to Novo’s current blockbuster injection, Wegovy.

The trial also indicated that amycretin has a similar safety profile to Wegovy and Ozempic, with common side effects including mild to moderate gastrointestinal issues like nausea, vomiting, and diarrhea. The pill targets the same GLP-1 hormone as other weight loss and diabetes drugs, as well as stimulating receptors for amylin, a hormone that regulates hunger.

While the results are promising, the study is still in its early stages and has not yet been published in a peer-reviewed journal. Novo Nordisk is continuing to evaluate amycretin, with plans to release more data in 2025. Depending on the results, the company may move forward with a larger Phase 3 trial.

The obesity drug market is rapidly expanding, with analysts predicting it could be worth up to $100 billion by the end of the decade. Novo Nordisk and Eli Lilly currently dominate this sector, but face competition from newer companies like Viking Therapeutics. Both companies are exploring new drugs and formulations, including weight loss pills, to stay ahead in the market.

See also  Large number of low-birth-weight babies born to women living near the Aliso Canyon gas blowout

Novo Nordisk’s stock saw a significant increase following the announcement of the amycretin trial results. The company’s focus on obesity drugs has helped solidify its position as one of Europe’s most valuable companies.

In conclusion, Novo Nordisk’s amycretin weight loss pill shows great promise in early trials, with the potential to outperform existing treatments. As the company continues to develop and evaluate the drug, the future of weight loss treatments looks increasingly exciting.

TAGGED:DrugearlyEffectiveLossNovosTrialWegovyWeight
Share This Article
Twitter Email Copy Link Print
Previous Article Stocks Fall as Bond Yields Rise After CPI Data: Markets Wrap Stocks Fall as Bond Yields Rise After CPI Data: Markets Wrap
Next Article Engaging Constitution Day Activities for Students – The TPT Blog Engaging Constitution Day Activities for Students – The TPT Blog
Leave a comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Popular Posts

WWE subtly hinted that Alexa Bliss won’t be joining The Wyatt Sicks

WWE fans were thrilled to see Alexa Bliss make her return to active programming last…

May 16, 2025

Burglary crew steals ATMs, cash in 10 break-ins since June

Businesses in Chicago have been put on high alert following a series of overnight burglaries…

July 23, 2025

“Electricity-Saving Boxes” Are Dangerous. Here’s How to Make Savings

The current economic climate has left many households struggling to make ends meet, with rising…

April 22, 2025

K2-18b: Astronomers double down on claim of strongest evidence for alien life

Have Astronomers Found Evidence of Alien Life on Exoplanet K2-18b? An artist’s impression of the…

May 20, 2025

Tense scenes as Chch terrorist’s referees give evidence

By Danielle Clent of RNZ Tensions ran high as the two referees for the Christchurch…

October 10, 2024

You Might Also Like

For cardiac health, exercise benefits women more than men
Health and Wellness

For cardiac health, exercise benefits women more than men

October 30, 2025
Hydrogen gas found to play key role in supporting gut health
Health and Wellness

Hydrogen gas found to play key role in supporting gut health

October 30, 2025
Alignment Healthcare Reports Second Profitable Quarter By Taming Costs
Health and Wellness

Alignment Healthcare Reports Second Profitable Quarter By Taming Costs

October 30, 2025
Blue Cross’ new algorithm for health care costs infuriates doctors
Health and Wellness

Blue Cross’ new algorithm for health care costs infuriates doctors

October 30, 2025
logo logo
Facebook Twitter Youtube

About US


Explore global affairs, political insights, and linguistic origins. Stay informed with our comprehensive coverage of world news, politics, and Lifestyle.

Top Categories
  • Crime
  • Environment
  • Sports
  • Tech and Science
Usefull Links
  • Contact
  • Privacy Policy
  • Terms & Conditions
  • DMCA

© 2024 americanfocus.online –  All Rights Reserved.

Welcome Back!

Sign in to your account

Lost your password?